Dijon

• ​​AMG 436 as monotherapy and combination therapy in participants with Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors … Recruiting
  2025-524056-63-00 1 2026-06-05 microsatellite instability high/mismatch repair deficient (MSI-H/dMMR)
• Evaluation of the efficacy and safety of Magnetic Resonance Angiography (MRA) using gadopiclenol compared to gadoterate meglumine in the ass … Recruiting
  2024-518835-13-00 5 2026-05-19 Suspected Vascular Disease of supra-aortic (carotid/vertebrobasilar),
• Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Recruiting
  2024-519655-28-00 5 2026-04-23 Premenopausal patients with high-risk HR-positive/HER2-negative breast
• MATRIX-IPC 2022-029 A phase I/II study evaluating Tuvusertib (M1774), an ATR Inhibitor, in combination with fulvestrant in hormone receptors … Recruiting
  2023-507485-10-00 9 2026-04-21 advanced breast cancer
• Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer ( R … Recruiting
  2024-519818-31-01 5 2026-04-10 Endometrial Cancer Advanced, Recurrent, Metastatic, or Primary Unresec
• CLEOPATTRA: A research study to look at the effects of treatment with a medicine called coramitug (NNC6019-0001) in people with heart failur … Recruiting
  2024-518899-31-00 5 2025-12-19 Variant or wild-type transthyretin (TTR) amyloid cardiomyopathy
• NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting
  2025-520979-13-00 5 2025-12-18 Patients with HR+ HER2- early breast cancer at intermediate risk of re
• A study to test how well an oral medication called rilzabrutinib works and how safe it is for adults with immune thrombocytopenia (ITP) who … Recruiting
  2025-522070-36-00 5 2025-12-15 immune thrombocytopenia (ITP)
• Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B- … Recruiting
  2025-520982-39-00 5 2025-12-09 Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-
• HER2DX-guided diagnostic treatment For patients with HER2-positive early-stage breast cancer Recruiting
  2025-521040-37-00 5 2025-11-26 HER2-positive early breast cancer
• A Study of Navlimetostat (BMS-986504) in Combination with Pembrolizumab Plus Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy … Recruiting
  2025-521511-40-00 10 2025-11-18 metastatic non-small cell lung cancer
• A Phase 1-2, Double-Blind, MAD Study of ION440 in MDS Recruiting
  2023-507192-22-00 7 2025-10-24 Methyl CpG binding protein 2 (MECP2) Duplication Syndrome (MDS)
• Phase 3 Study of T-DXd and Rilvegostomig versus Standard of Care in Advanced HER2-expressing Biliary Tract Cancer Recruiting
  2023-508057-19-00 5 2025-09-23 Advanced HER2-expressing Biliary Tract Cancer
• Selective Treatment of Oral Povorcitinib Long-Term Rollover Study (STOP-LTR) Recruiting
  2024-520107-12-00 5 2025-09-03 Hidradenitis Suppurativa // Prurigo Nodularis // Vitiligo
• A Study of YL201 in Patients With Advanced Solid Tumors Recruiting
  2024-517589-41-00 1 2025-08-04 Advanced solid tumors
• A Study to Investigate the Safety and Efficacy of Pirtobrutinib in Adults with Immune Thrombocytopenia Recruiting
  2024-518502-40-00 9 2025-07-28 Immune Thrombocytopenia
• A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with … Recruiting
  2024-513965-38-01 5 2025-06-16 Sjögren's Disease
• A study evaluating the effects of filgotinib in children and teenagers with ulcerative colitis Recruiting
  2024-511458-32-00 5 2025-06-15 Ulcerative colitis
• Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Pancreatic Cancer (Substudy PDAC) Recruiting
  2024-517819-74-00 9 2025-06-02 Pancreatic Ductal Adenocarcinoma
• A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab a … Recruiting
  2023-505172-29-00 4 2025-04-24 Resectable Non-small Cell Lung Cancer
• Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C … Recruiting
  2024-515445-42-00 5 2025-03-24 Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
• A study to assess the Efficacy and Safety of Efgartigimod IV in Adult Participants with Primary Immune Thrombocytopenia Recruiting
  2024-515451-38-00 5 2025-02-27 Primary Immune thrombocytopenia (ITP)
• Randomized Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Ade … Recruiting
  2024-513317-12-00 5 2025-02-05 Pancreatic cancer
• HEPATIC ARTERIAL INFUSION OF GEMCITABINE-OXALIPLATIN FOR SECOND-LINE THERAPY IN NON-METASTATIC UNRESECTABLE INTRA-HEPATIC CHOLANGIOCARCINOMA … Recruiting
  2024-519132-17-00 4 2025-01-29 NON-METASTATIC UNRESECTABLE INTRA-HEPATIC CHOLANGIOCARCINOMA

Showing 97–120 of 825 trials